Salim, Hotimah Masdan and et. al, . (2017) Canagliflozin Reduces Epicardial Fat in Patients with Type 2 Diabetes Mellitus. Diabetology & Metabolic Syndrome, 9 (1). pp. 1-7. ISSN 1758-5996
|
PDF
Canagliflozin Reduces Epicardial Fat in Patients with Type 2 Diabetes Mellitus.pdf Download (984kB) | Preview |
|
|
PDF
peer review.pdf Download (1MB) | Preview |
|
|
PDF
turnitin.pdf Download (3MB) | Preview |
Abstract
Background: It is unknown whether canagliflozin, a selective sodium glucose co‑transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. Methods and results: We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Cana‑ gliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes. Conclusion: Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327).
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Epicardial adipose tissue, SGLT2 inhibitors, Echocardiography |
| Subjects: | R Medicine > RC Internal medicine > RC581-951 Specialties of internal medicine |
| Divisions: | Faculty of Medicine > Program Study of Medicine |
| Depositing User: | Mr. . Aji |
| Date Deposited: | 20 Mar 2019 05:08 |
| Last Modified: | 26 Mar 2019 10:28 |
| URI: | http://repository.unusa.ac.id/id/eprint/3842 |
Actions (login required)
 |
View Item |
